Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4590107 | 0.90 | LMNA (0.36) | LMNA | |
| SCHEMBL4589648 | 0.86 | LMNA (0.30) | LMNA | |
| SCHEMBL4589645 | 0.77 | — | — | |
| SCHEMBL4589957 | 0.76 | LMNA (0.37) | LMNASMN1; SMN2 | |
| SCHEMBL4589208 | 0.72 | LMNA (0.36) | LMNASMN1; SMN2 | |
| SCHEMBL4589516 | 0.71 | — | — | |
| SCHEMBL5555241 | 0.69 | LMNA (0.38) | LMNASMN1; SMN2 | |
| SCHEMBL7797725 | 0.69 | LMNA (0.60) | LMNASMN1; SMN2 | |
| SCHEMBL7797724 | 0.69 | LMNA (0.60) | LMNASMN1; SMN2 | |
| SCHEMBL4589188 | 0.68 | LMNA (0.38) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7385054-B2 | Trimeric, macrocyclically substituted halo-benzene derivatives | SCHERING AG (DE) | 2008-06-10 | — | — | US | disclosed |
| US-20060154989-A1 | Trimeric, macrocyclically substituted halo-benzene derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154989-A1 | Trimeric, macrocyclically substituted halo-benzene derivatives | BOLA2; BOLA2B, BRI3BP, ARRB1 | LMNA 2174/4885SMN1; SMN2 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.